Wai Yuen Tong Medicine Holdings Limited (HKG:0897)
Hong Kong
· Delayed Price · Currency is HKD 0.3600
+0.0100 (2.86%)
Apr 24, 2025, 3:28 PM HKT
HKG:0897 Revenue
Wai Yuen Tong Medicine Holdings had revenue of 346.84M HKD in the half year ending September 30, 2024, a decrease of -42.78%. This brings the company's revenue in the last twelve months to 762.40M, up 26.08% year-over-year. In the fiscal year ending March 31, 2024, Wai Yuen Tong Medicine Holdings had annual revenue of 783.88M with 8.33% growth.
Revenue (ttm)
762.40M
Revenue Growth
+26.08%
P/S Ratio
0.53
Revenue / Employee
933.17K
Employees
810
Market Cap
405.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 783.88M | 60.28M | 8.33% |
| Mar 31, 2023 | 723.60M | -667.81M | -48.00% |
| Mar 31, 2022 | 1.39B | 282.85M | 25.51% |
| Mar 31, 2021 | 1.11B | 487.82M | 78.59% |
| Mar 31, 2020 | 620.74M | -130.70M | -17.39% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Akeso | 2.26B |
| Innovent Biologics | 10.03B |
| Alibaba Health Information Technology | 31.39B |
| CSPC Pharmaceutical Group | 30.87B |